Contrasting influences of renal function on blood pressure and HbA1c reductions with empagliflozin: Pooled analysis of phase III trials

Objective: Glucose lowering with empagliflozin is dependent on renal function. We investigated the influence of chronic kidney disease (CKD) on changes in HbA1c and blood pressure (BP) with empagliflozin. Methods: Using pooled data from five, 24-week randomized Phase III trials in patients with type 2 diabetes (T2DM), we assessed changes from baseline in systolic BP (SBP) and HbA1c with empagliflozin 25 mg versus placebo in subgroups by baseline eGFR (MDRD equation; normal renal function [≥90 mL/min/1.73 m2], stage 2 CKD [≥60 to < 90 mL/min/1.73 m2], stage 3 CKD [≥30 to < 60 mL/min/1.73 m2] and stage 4 CKD [< 30…